TrialInvestigational new drugs2025

Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors.

Judy S Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.